Search results
Oct 9, 2024 · TOKYO, Oct. 8, 2024 /PRNewswire/ --Ciconia Bioventures Inc. (Representative Director, Founder CEO: Toshio Fujimoto, "Ciconia") today announced its establishment as a joint venture company based on ...
Sep 24, 2024 · in The Lancet in June 2023. 2,1. Takeda’s Commitment to Colorectal Cancer in Japan. CRC is the most prevalent type of cancer in Japan, with an estimated 161,000 new cases and 54,000 deaths in 2023, according to the National Cancer Center’s statistics. 3 While early-stage CRC can be surgically resected, mCRC remains an area of high unmet need with patients awaiting new treatment options ...
Oct 8, 2024 · Yoshinori Takeda 4, Chiho Fuseya 5, Makoto Nomiyama 6, Takafumi Ushida 7, Kazushi Watanabe 8, Yumi Kono 9, Katsuhiko Naruse 10, Hiroyuki Seki 11 & ...
3 days ago · Views & Analysis. As part of our Women in Pharma series, where we talk to leading figures in the life sciences, we hear from Şeyda Atadan Memiş, recently appointed general manager for Takeda UK ...
Oct 1, 2024 · Yoshinori Sudo: General Manager, Human Resources: Executive Officer: Mitsutaka Kajiya: Head of Investment Management & Advisory: Executive Officer: Takaaki Inoue: Head of Corporate Finance (Industrials Group and Industrial Research & Sustainable Solutions) Executive Officer: Katsuya Fujita: Senior Deputy Head of Global Markets Planning
Oct 2, 2024 · Yoshinori Takeda is currently associated with 1 company as Alternate Director. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 10204497. Yoshinori Takeda is currently involved in 1 different role. Their most recent position is with PUSHPSONS FIBROL PRIVATE LIMITED as a Alt...
Oct 1, 2024 · The safety of major hepatectomy following preoperative chemotherapy for perihilar cholangiocarcinoma (PHCC) is underexplored. This study evaluates the impact of preoperative chemotherapy on surgical outcomes and assesses chemotherapy-induced liver injury in patients with advanced PHCC.
